M. S. Gelman, R. R. Kopito: Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. In: Methods in molecular biology. Band 232, 2003, S. 27–37, doi:10.1385/1-59259-394-1:27, PMID 12840537 (Review).
S. C. Bell, K. De Boeck, M. D. Amaral: New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. In: Pharmacology & therapeutics. Band 145, Januar 2015, S. 19–34, doi:10.1016/j.pharmthera.2014.06.005, PMID 24932877.
J. L. Bobadilla, M. Macek u. a.: Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. In: Human mutation. Band 19, Nummer 6, Juni 2002, S. 575–606, doi:10.1002/humu.10041, PMID 12007216 (Review).
C. Castellani, H. Cuppens u. a.: Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. In: Journal of cystic fibrosis. Band 7, Nummer 3, Mai 2008, S. 179–196, doi:10.1016/j.jcf.2008.03.009, PMID 18456578, PMC 2810954 (freier Volltext) (Review).
N. Morral, J. Bertranpetit u. a.: The origin of the major cystic fibrosis mutation (delta F508) in European populations. In: Nature genetics. Band 7, Nummer 2, Juni 1994, S. 169–175, doi:10.1038/ng0694-169, PMID 7920636.
X. Estivill, C. Bancells, C. Ramos: Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. In: Human mutation. Band 10, Nummer 2, 1997, S. 135–154, doi:10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.0.CO;2-J, PMID 9259197.
O. Lao, A. M. Andrés u. a.: Spatial patterns of cystic fibrosis mutation spectra in European populations. In: European journal of human genetics. Band 11, Nummer 5, Mai 2003, S. 385–394, doi:10.1038/sj.ejhg.5200970, PMID 12734544.
J. Sanz, T. von Känel u. a.: The CFTR frameshift mutation 3905insT and its effect at transcript and protein level. In: European journal of human genetics. Band 18, Nummer 2, Februar 2010, S. 212–217, doi:10.1038/ejhg.2009.140, PMID 19724303, PMC 2987192 (freier Volltext).
R. Sebro, H. Levy u. a.: Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. In: Clinical genetics. Band 82, Nummer 6, Dezember 2012, S. 546–551, doi:10.1111/j.1399-0004.2011.01804.x, PMID 22035343, PMC 4279028 (freier Volltext).
M. D. Amaral: CFTR and chaperones: processing and degradation. In: Journal of molecular neuroscience. Band 23, Nummer 1–2, 2004, S. 41–48, doi:10.1385/JMN:23:1-2:041, PMID 15126691 (Review).
S. J. Kim, W. R. Skach: Mechanisms of CFTR Folding at the Endoplasmic Reticulum. In: Frontiers in pharmacology. Band 3, 2012, S. 201, doi:10.3389/fphar.2012.00201, PMID 23248597, PMC 3521238 (freier Volltext).
D. N. Hebert, M. Molinari: In and out of the ER: protein folding, quality control, degradation, and related human diseases. In: Physiological reviews. Band 87, Nummer 4, Oktober 2007, S. 1377–1408, doi:10.1152/physrev.00050.2006, PMID 17928587 (Review).
W. B. Guggino: Cystic fibrosis salt/fluid controversy: in the thick of it. In: Nature medicine. Band 7, Nummer 8, August 2001, S. 888–889, doi:10.1038/90914, PMID 11479614.
E. F. McKone, S. S. Emerson u. a.: Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. In: The Lancet. Band 361, Nummer 9370, Mai 2003, S. 1671–1676, doi:10.1016/S0140-6736(03)13368-5, PMID 12767731.
M. P. Boyle, K. De Boeck: A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. In: The Lancet. Respiratory medicine. Band 1, Nummer 2, April 2013, S. 158–163, doi:10.1016/S2213-2600(12)70057-7, PMID 24429096 (Review).
A. M. Cantin, G. Bilodeau u. a.: Oxidant stress suppresses CFTR expression. In: American journal of physiology. Cell physiology. Band 290, Nummer 1, Januar 2006, S. C262–C270, doi:10.1152/ajpcell.00070.2005, PMID 16162662.
A. M. Cantin, J. W. Hanrahan u. a.: Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. In: American journal of respiratory and critical care medicine. Band 173, Nummer 10, Mai 2006, S. 1139–1144, doi:10.1164/rccm.200508-1330OC, PMID 16497995.
E. F. McKone, J. Shao u. a.: Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. In: American journal of respiratory and critical care medicine. Band 174, Nummer 4, August 2006, S. 415–419, doi:10.1164/rccm.200508-1281OC, PMID 16690975, PMC 2648118 (freier Volltext).
T. Flass, M. R. Narkewicz: Cirrhosis and other liver disease in cystic fibrosis. In: Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society. Band 12, Nummer 2, März 2013, S. 116–124, doi:10.1016/j.jcf.2012.11.010, PMID 23266093, PMC 3883947 (freier Volltext).
N. C. Dean, D. H. Van Boerum, T. G. Liou: Rib plating of acute and sub-acute non-union rib fractures in an adult with cystic fibrosis: a case report. In: BMC research notes. Band 7, 2014, S. 681, doi:10.1186/1756-0500-7-681, PMID 25270323, PMC 4197343 (freier Volltext).
R. M. Javier, J. Jacquot: Bone disease in cystic fibrosis: what’s new? In: Joint, bone, spine. Band 78, Nummer 5, Oktober 2011, S. 445–450, doi:10.1016/j.jbspin.2010.11.015, PMID 21233000 (Review).
L. S. Conwell, A. B. Chang: Bisphosphonates for osteoporosis in people with cystic fibrosis. In: The Cochrane database of systematic reviews. Band 3, 2014, S. CD002010, doi:10.1002/14651858.CD002010.pub4, PMID 24627308 (Review).
G. Döring, S. P. Conway: Osteoporosis in cystic fibrosis. In: Jornal de pediatria. Band 84, Nummer 1, 2008, S. 1–3, doi:10.2223/JPED.1749, PMID 18264617.
E. F. Shead, C. S. Haworth u. a.: Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. In: Journal of cystic fibrosis. Band 9, Nummer 2, März 2010, S. 93–98, doi:10.1016/j.jcf.2009.11.007, PMID 20006563.
E. F. Shead, C. S. Haworth u. a.: Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. In: American journal of respiratory and critical care medicine. Band 174, Nummer 3, August 2006, S. 306–311, doi:10.1164/rccm.200512-1943OC, PMID 16675777.
E. F. Shead, C. S. Haworth u. a.: Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. In: Thorax. Band 62, Nummer 7, Juli 2007, S. 650–651, doi:10.1136/thx.2006.075887, PMID 17600296, PMC 2117234 (freier Volltext).
L. Le Heron, C. Guillaume u. a.: Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. In: Journal of cystic fibrosis. Band 9, Nummer 1, Januar 2010, S. 69–72, doi:10.1016/j.jcf.2009.11.005, PMID 20005786.
E. Shane, S. J. Silverberg u. a.: Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. In: The American journal of medicine. Band 101, Nummer 3, September 1996, S. 262–269, doi:10.1016/S0002-9343(96)00155-6, PMID 8873487.
J. Yu, Z. Chen u. a.: CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. In: Human reproduction. Band 27, Nummer 1, Januar 2012, S. 25–35, doi:10.1093/humrep/der377, PMID 22081250 (Review).
J. Massie, B. Clements: Diagnosis of cystic fibrosis after newborn screening: the Australasian experience–twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group. In: Pediatric pulmonology. Band 39, Nummer 5, Mai 2005, S. 440–446, doi:10.1002/ppul.20191, PMID 15704202 (Review).
M. Stopsack, J. Hammermann: Neugeborenenscreening auf Mukoviszidose. In: Monatsschrift Kinderheilkunde. Band 157, Nummer 12, S. 1222–1229 doi:10.1007/s00112-009-2042-6
V. Teichgräber, M. Ulrich u. a.: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. In: Nature medicine. Band 14, Nummer 4, April 2008, S. 382–391, doi:10.1038/nm1748, PMID 18376404.
J. Kornhuber, M. Muehlbacher u. a.: Identification of novel functional inhibitors of acid sphingomyelinase. In: PloS one. Band 6, Nummer 8, 2011, S. e23852, doi:10.1371/journal.pone.0023852, PMID 21909365, PMC 3166082 (freier Volltext).
E. M. Welch, E. R. Barton u. a.: PTC124 targets genetic disorders caused by nonsense mutations. In: Nature. Band 447, Nummer 7140, Mai 2007, S. 87–91, doi:10.1038/nature05756, PMID 17450125.
G. L. McPhail, J. P. Clancy: Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. In: Drugs of today. Band 49, Nummer 4, April 2013, S. 253–260, doi:10.1358/dot.2013.49.4.1940984, PMID 23616952.
K. Kotha, J. P. Clancy: Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. In: Therapeutic advances in respiratory disease. Band 7, Nummer 5, Oktober 2013, S. 288–296, doi:10.1177/1753465813502115, PMID 24004658 (Review).
I. Sermet-Gaudelus: Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. In: European respiratory review. Band 22, Nummer 127, März 2013, S. 66–71, doi:10.1183/09059180.00008512, PMID 23457167 (Review).
L. Regard, C. Martin, J. Da Silva, P.-R. Burgel: CFTR modulators: current status and evolving knowledge.Semin. Respir. Crit. Care Med., im Druck. doi:10.1055/s-0042-1758851
J. C. Davies, E. W. Alton: Design of gene therapy trials in CF patients. In: Methods in molecular biology (Clifton, N.J.). Band 741, 2011, S. 55–68, doi:10.1007/978-1-61779-117-8_5, PMID 21594778 (Review).
I. Sermet-Gaudelus, K. D. Boeck u. a.: Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. In: American journal of respiratory and critical care medicine. Band 182, Nummer 10, November 2010, S. 1262–1272, doi:10.1164/rccm.201001-0137OC, PMID 20622033.
T. Iannitti, B. Palmieri: Clinical and experimental applications of sodium phenylbutyrate. In: Drugs in R&D. Band 11, Nummer 3, September 2011, S. 227–249, doi:10.2165/11591280-000000000-00000, PMID 21902286, PMC 3586072 (freier Volltext) (Review).
P. L. Zeitlin, M. Diener-West u. a.: Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. In: Molecular therapy. Band 6, Nummer 1, Juli 2002, S. 119–126, doi:10.1006/mthe.2002.0639, PMID 12095312.
M. Favia, M. T. Mancini u. a.: Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. In: American journal of physiology. Lung cellular and molecular physiology. Band 307, Nummer 1, Juli 2014, S. L48–L61, doi:10.1152/ajplung.00305.2013, PMID 24816489.
J. F. Collawn, L. Fu u. a.: Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator. In: American journal of physiology. Band 307, Nummer 6, September 2014, S. L431–L434, doi:10.1152/ajplung.00177.2014, PMID 25063802, PMC 4166784 (freier Volltext) (Review).
T. S. Cohen, A. Prince: Cystic fibrosis: a mucosal immunodeficiency syndrome. In: Nature medicine. Band 18, Nummer 4, April 2012, S. 509–519, doi:10.1038/nm.2715, PMID 22481418, PMC 3577071 (freier Volltext) (Review).
R. Rozmahel, M. Wilschanski u. a.: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. In: Nature genetics. Band 12, Nummer 3, März 1996, S. 280–287, doi:10.1038/ng0396-280, PMID 8589719.
C. S. Rogers, Y. Hao u. a.: Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. In: The Journal of clinical investigation. Band 118, Nummer 4, April 2008, S. 1571–1577, doi:10.1172/JCI34773, PMID 18324337, PMC 2265103 (freier Volltext).
Y. Song, W. Namkung u. a.: Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: dependence on Na+ and Cl- channel function. In: American journal of physiology. Lung cellular and molecular physiology. Band 297, Nummer 6, Dezember 2009, S. L1131–L1140, doi:10.1152/ajplung.00085.2009, PMID 19820035, PMC 2793186 (freier Volltext).
X. Sun, H. Sui u. a.: Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. In: The Journal of clinical investigation. Band 120, Nummer 9, September 2010, S. 3149–3160, doi:10.1172/JCI43052, PMID 20739752, PMC 2929732 (freier Volltext).
N. W. Keiser, J. F. Engelhardt: New animal models of cystic fibrosis: what are they teaching us? In: Current opinion in pulmonary medicine. Band 17, Nummer 6, November 2011, S. 478–483, doi:10.1097/MCP.0b013e32834b14c9, PMID 21857224, PMC 3596000 (freier Volltext) (Review).
P. B. Davis: Cystic fibrosis since 1938. In: American journal of respiratory and critical care medicine. Band 173, Nummer 5, März 2006, S. 475–482, doi:10.1164/rccm.200505-840OE, PMID 16126935 (Review).
L. K. Tuchman, L. A. Schwartz u. a.: Cystic fibrosis and transition to adult medical care. In: Pediatrics. Band 125, Nummer 3, März 2010, S. 566–573, doi:10.1542/peds.2009-2791, PMID 20176665 (Review).
J. L. Kreindler, V. A. Miller: Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care. In: Patient preference and adherence. Band 7, 2013, S. 1221–1226, doi:10.2147/PPA.S37710, PMID 24376344, PMC 3864992 (freier Volltext) (Review).
B. S. Quon, W. D. Bentham u. a.: Prevalence of Symptoms of Depression and Anxiety in Adults With Cystic Fibrosis Based on the PHQ-9 and GAD-7 Screening Questionnaires. In: Psychosomatics. [elektronische Veröffentlichung vor dem Druck] Juni 2014, doi:10.1016/j.psym.2014.05.017, PMID 25556569.
T. A. VanWort, J. A. Lee u. a.: Female cystic fibrosis mutation carriers and assisted reproductive technology: does carrier status affect reproductive outcomes? In: Fertility and sterility. Band 102, Nummer 5, November 2014, S. 1324–1330, doi:10.1016/j.fertnstert.2014.07.1234, PMID 25217870.
I. Gallego Romero, C. Ober: CFTR mutations and reproductive outcomes in a population isolate. In: Human genetics. Band 122, Nummer 6, Januar 2008, S. 583–588, doi:10.1007/s00439-007-0432-1, PMID 17901983.
M. Dahl, A. Tybjaerg-Hansen u. a.: Cystic fibrosis Delta F508 heterozygotes, smoking, and reproduction: studies of 9141 individuals from a general population sample. In: Genomics. Band 50, Nummer 1, Mai 1998, S. 89–96, doi:10.1006/geno.1998.5272, PMID 9628826.
S. V. Raju, J. H. Tate u. a.: Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. In: Respiratory research. Band 15, 2014, S. 18, doi:10.1186/1465-9921-15-18, PMID 24517344, PMC 3925354 (freier Volltext).
J. J. Guo, D. A. Stoltz u. a.: Genotype-specific alterations in vascular smooth muscle cell function in cystic fibrosis piglets. In: Journal of cystic fibrosis. Band 13, Nummer 3, Mai 2014, S. 251–259, doi:10.1016/j.jcf.2013.10.009, PMID 24183914, PMC 3972271 (freier Volltext).
V. A. Peotta, P. Bhandary u. a.: Reduced blood pressure of CFTR-F508del carriers correlates with diminished arterial reactivity rather than circulating blood volume in mice. In: PloS one. Band 9, Nummer 5, 2014, S. e96756, doi:10.1371/journal.pone.0096756, PMID 24801204, PMC 4011854 (freier Volltext).
S. Rendine, F. Calafell u. a.: Genetic history of cystic fibrosis mutations in Italy. I. Regional distribution. In: Annals of Human Genetics. Band 61, 1997, S. 411–424, doi:10.1046/j.1469-1809.1997.6150411.x, PMID 9459003.
G. B. Pier, M. Grout u. a.: Salmonella typhi uses CFTR to enter intestinal epithelial cells. In: Nature. Band 393, Nummer 6680, Mai 1998, S. 79–82, doi:10.1038/30006, PMID 9590693.
E. van de Vosse, S. Ali u. a.: Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). In: Human genetics. Band 118, Nummer 1, Oktober 2005, S. 138–140, doi:10.1007/s00439-005-0005-0, PMID 16078047.
E. M. Poolman, A. P. Galvani: Evaluating candidate agents of selective pressure for cystic fibrosis. In: Journal of the Royal Society. Band 4, Nummer 12, Februar 2007, S. 91–98, doi:10.1098/rsif.2006.0154, PMID 17015291, PMC 2358959 (freier Volltext).
A. L. Hughes, R. Friedman, M. Murray: Genomewide pattern of synonymous nucleotide substitution in two complete genomes of Mycobacterium tuberculosis. In: Emerging infectious diseases. Band 8, Nummer 11, November 2002, S. 1342–1346, doi:10.3201/eid0811.020064, PMID 12453367, PMC 2738538 (freier Volltext).
U. Stephan, M. Götz, K. Stephan, S. Bender: Cystic Fibrosis. In: P. Frick, G.-A. von Harnack, G. A. Martini, A. Prader, H. P. Wolff (Hrsg.): Advances in Internal Medicine and Pediatrics. Band 44, Springer Berlin Heidelberg, 1980, ISBN 978-3-642-67559-1, S. 73–174 doi:10.1007/978-3-642-67557-7_3
S. Zabransky, S. Isabel Zink: IRT-Bestimmung in Vollblutproben getrocknet auf Filterpapier als Suchtest auf Cystische Fibrose In: Siegfried Zabransky (Hrsg.): Screening auf angeborene endokrine und metabole Störungen. 2001, S. 269–296 doi:10.1007/978-3-7091-6252-1_33, ISBN 978-3-7091-7260-5
C. U. Lowe, C. D. May, S. C. Reed: Fibrosis of the pancreas in infants and children; a statistical study of clinical and hereditary features. In: American journal of diseases of children. Band 78, Nummer 3, September 1949, S. 349–374, doi:10.1001/archpedi.1949.02030050362008, PMID 18138931.
Sabina Gallati: Funktion von CFTR als Chloridkanal an der Plasmamembran. In: Dietrich Reinhardt, Manfred Götz, Richard Kraemer, Martin H. Schöni (Hrsg.): Cystische Fibrose. Springer-Verlag, 2013, ISBN 978-3-642-56796-4, S. 1–19 (eingeschränkte Vorschau in der Google-Buchsuche).
Sabina Gallati, Dominik Hartl u. a.: Zystische Fibrose. In: Erika von Mutius, Monika Gappa u. a.: Pädiatrische Pneumologie. Springer-Verlag, 2013, ISBN 3-642-34827-0, S. 587–632 (eingeschränkte Vorschau in der Google-Buchsuche)
V. Im Hof, P. Gehr: Mukoziliäre Clearance. In: Christian Rieger, Horst von der Hardt u. a. (Hrsg.): Pädiatrische Pneumologie. 2. Auflage, Springer-Verlag, 2013, ISBN 3-662-09182-8, S. 110–117 (eingeschränkte Vorschau in der Google-Buchsuche)
Andrew Bush: Cystic Fibrosis. In: John A. Goodfellow (Hrsg.): Understanding Medical Research: The Studies That Shaped Medicine. John Wiley & Sons, 2012, ISBN 1-119-96373-7, S. 88 eingeschränkte Vorschau in der Google-Buchsuche
C. Randak, Burckhardt Tümmler: Funktion von CFTR als Chloridkanal an der Plasmamembran. In: Dietrich Reinhardt, Manfred Götz, Richard Kraemer, Martin H. Schöni (Hrsg.): Cystische Fibrose. Springer-Verlag, 2013, ISBN 978-3-642-56796-4, S. 29–33 (eingeschränkte Vorschau in der Google-Buchsuche).
T. O. Hirche, T. O. F. Wagner: Mukoviszidose (cystische Fibrose). In: Heinrich Matthys, Werner Seeger: Klinische Pneumologie. 4. Auflage, Springer Science & Business Media, 2008, ISBN 3-540-37682-8, S. 280–295 eingeschränkte Vorschau in der Google-Buchsuche
J. Hein: Mukoviszidose (cystische Fibrose). In: Nikolaus Konietzko, H. Wendel, B. Wiesner: Erkrankungen der Lunge. Walter de Gruyter, 1994, ISBN 3-11-012130-1, S. 619 (eingeschränkte Vorschau in der Google-Buchsuche)
J. Herwig, H. Böhles: Diabete mellitus im Kinder und Jugendalter. In: Hellmut Mehnert, Eberhard Standl u. a. (Hrsg.): Diabetologie in Klinik und Praxis. 5. Auflage, Georg Thieme Verlag, 2003, ISBN 3-13-512805-9, S. 341 (eingeschränkte Vorschau in der Google-Buchsuche)
Gerhard Dockter, Hermann Lindemann: Genetik, Molekularbiologie und allgemeine Pathophysiologie. In: Hermann Lindemann, Burckhardt Tümmler, Gerhard Dockter (Hrsg.): Mukoviszidose – Zystische Fibrose. 4. Auflage, Georg Thieme, 2004, ISBN 3-13-138604-5, S. 3–13 eingeschränkte Vorschau in der Google-Buchsuche
Claus Kroegel, Ulrich Costabel: Klinische Pneumologie: Das Referenzwerk für Klinik und Praxis. Georg Thieme, 2013, ISBN 3-13-175781-7, S. 655 eingeschränkte Vorschau in der Google-Buchsuche
M. J. Müller, J. Westenhöfer u. a.: Ernährungsmedizinische Untersuchungen. In: Manfred James Müller: Ernährungsmedizinische Praxis: Methoden - Prävention - Behandlung. 2. Auflage, Springer-Verlag, 2007, ISBN 3-540-38231-3, S. 162 eingeschränkte Vorschau in der Google-Buchsuche
Udo Wendel, Martin Lindner, Markus Bettendorf: Neugeborenen-Screening in Deutschland. Schattauer Verlag, 2009, ISBN 3-7945-2686-4, S. 78 eingeschränkte Vorschau in der Google-Buchsuche
Peter Hien: Praktische Pneumologie. Kapitel 56: Zystische Fibrose. 2. Auflage, Springer-Verlag, 2011, ISBN 3-642-10209-3, S. 185 (eingeschränkte Vorschau in der Google-Buchsuche)
Peter Hien: Praktische Pneumologie. Kapitel 56: Zystische Fibrose. 2. Auflage, Springer-Verlag, 2011, ISBN 3-642-10209-3, S. 479–484 (eingeschränkte Vorschau in der Google-Buchsuche)
Irmgard Eichler: Zystische Fibrose (Mukoviszidose). In: Christian P. Speer, Manfred Gahr (Hrsg.): Pädiatrie. Springer-Verlag, 2013, ISBN 3-662-09178-X, S. 558–565 eingeschränkte Vorschau in der Google-Buchsuche
Heike Bickeböller, Christine Fischer: Einführung in die Genetische Epidemiologie. Springer-Verlag, 2007, ISBN 3-540-33568-4, S. 73 eingeschränkte Vorschau in der Google-Buchsuche
Gerhard Dockter, Hermann Lindemann: Einleitung und Grundlagen. In: Hermann Lindemann, Burckhardt Tümmler, Gerhard Dockter (Hrsg.): Mukoviszidose – Zystische Fibrose. 4. Auflage, Georg Thieme, 2004, ISBN 3-13-138604-5, S. 1–2 eingeschränkte Vorschau in der Google-Buchsuche
Ulrich Grossekettler: Erhöhte Serum-Konzentrationen von IL-18 und IL-12 p40 bei Mukoviszidose Dissertation, Johann Wolfgang Goethe-Universität Frankfurt am Main, 2005, S. 5 eingeschränkte Vorschau in der Google-Buchsuche
James M. Littlewood: History of cystic fibrosis. In: Margaret Hodson, Andrew Bush, Duncan Geddes: Cystic Fibrosis. 3. Auflage, CRC Press, 2012, ISBN 978-1-4441-1369-3, S. 3–19 (eingeschränkte Vorschau in der Google-Buchsuche).
M. Griese, D. Reinhardt: Differentialdiagnose pathologischer Schweißtestresultate. In: Dietrich Reinhardt, Manfred Götz, Richard Kraemer, Martin H. Schöni (Hrsg.): Cystische Fibrose. Springer-Verlag, 2013, ISBN 978-3-642-56796-4, S. 212 (eingeschränkte Vorschau in der Google-Buchsuche).
J. X. Pfyffer: Zitierend aus dem Wörterbuch der Schweizerdeutschen Sprache Band 7, 1848, S. 899. Siehe dazu: James L. Littlewood: History of cystic fibrosis. In: Margaret Hodson, Andrew Bush, Duncan Geddes: Cystic Fibrosis. 3. Auflage, CRC Press, 2012, ISBN 978-1-4441-1369-3, 486 S. (eingeschränkte Vorschau in der Google-Buchsuche)
M. S. Gelman, R. R. Kopito: Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. In: Methods in molecular biology. Band 232, 2003, S. 27–37, doi:10.1385/1-59259-394-1:27, PMID 12840537 (Review).
S. C. Bell, K. De Boeck, M. D. Amaral: New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. In: Pharmacology & therapeutics. Band 145, Januar 2015, S. 19–34, doi:10.1016/j.pharmthera.2014.06.005, PMID 24932877.
M. Hergersberg, J. Balakrishnan u. a.: A new mutation, 3905insT, accounts for 4.8% of 1173 CF chromosomes in Switzerland and causes a severe phenotype. In: Human genetics. Band 100, Nummer 2, August 1997, S. 220–223, PMID 9254853.
G. Romeo, M. Devoto, L. J. Galietta: Why is the cystic fibrosis gene so frequent? In: Human genetics. Band 84, Nummer 1, Dezember 1989, S. 1–5, PMID 2691388 (Review).
G. Lucotte, S. Hazout, M. De Braekeleer: Complete map of cystic fibrosis mutation DF508 frequencies in Western Europe and correlation between mutation frequencies and incidence of disease. In: Human biology. Band 67, Nummer 5, Oktober 1995, S. 797–803, PMID 8543293.
J. L. Bobadilla, M. Macek u. a.: Cystic fibrosis: a worldwide analysis of CFTR mutations–correlation with incidence data and application to screening. In: Human mutation. Band 19, Nummer 6, Juni 2002, S. 575–606, doi:10.1002/humu.10041, PMID 12007216 (Review).
Y. Yamashiro, T. Shimizu u. a.: The estimated incidence of cystic fibrosis in Japan. In: Journal of pediatric gastroenterology and nutrition. Band 24, Nummer 5, Mai 1997, S. 544–547, PMID 9161949.
C. Castellani, H. Cuppens u. a.: Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. In: Journal of cystic fibrosis. Band 7, Nummer 3, Mai 2008, S. 179–196, doi:10.1016/j.jcf.2008.03.009, PMID 18456578, PMC 2810954 (freier Volltext) (Review).
N. Morral, J. Bertranpetit u. a.: The origin of the major cystic fibrosis mutation (delta F508) in European populations. In: Nature genetics. Band 7, Nummer 2, Juni 1994, S. 169–175, doi:10.1038/ng0694-169, PMID 7920636.
X. Estivill, C. Bancells, C. Ramos: Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. In: Human mutation. Band 10, Nummer 2, 1997, S. 135–154, doi:10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.0.CO;2-J, PMID 9259197.
O. Lao, A. M. Andrés u. a.: Spatial patterns of cystic fibrosis mutation spectra in European populations. In: European journal of human genetics. Band 11, Nummer 5, Mai 2003, S. 385–394, doi:10.1038/sj.ejhg.5200970, PMID 12734544.
J. Sanz, T. von Känel u. a.: The CFTR frameshift mutation 3905insT and its effect at transcript and protein level. In: European journal of human genetics. Band 18, Nummer 2, Februar 2010, S. 212–217, doi:10.1038/ejhg.2009.140, PMID 19724303, PMC 2987192 (freier Volltext).
R. Sebro, H. Levy u. a.: Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. In: Clinical genetics. Band 82, Nummer 6, Dezember 2012, S. 546–551, doi:10.1111/j.1399-0004.2011.01804.x, PMID 22035343, PMC 4279028 (freier Volltext).
M. D. Amaral: CFTR and chaperones: processing and degradation. In: Journal of molecular neuroscience. Band 23, Nummer 1–2, 2004, S. 41–48, doi:10.1385/JMN:23:1-2:041, PMID 15126691 (Review).
S. J. Kim, W. R. Skach: Mechanisms of CFTR Folding at the Endoplasmic Reticulum. In: Frontiers in pharmacology. Band 3, 2012, S. 201, doi:10.3389/fphar.2012.00201, PMID 23248597, PMC 3521238 (freier Volltext).
D. N. Hebert, M. Molinari: In and out of the ER: protein folding, quality control, degradation, and related human diseases. In: Physiological reviews. Band 87, Nummer 4, Oktober 2007, S. 1377–1408, doi:10.1152/physrev.00050.2006, PMID 17928587 (Review).
C. L. Ward, S. Omura, R. R. Kopito: Degradation of CFTR by the ubiquitin-proteasome pathway. In: Cell. Band 83, Nummer 1, Oktober 1995, S. 121–127, PMID 7553863.
J. R. Riordan, J. M. Rommens u. a.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. In: Science. Band 245, Nummer 4922, September 1989, S. 1066–1073, PMID 2475911.
D. N. Sheppard, M. J. Welsh: Structure and function of the CFTR chloride channel. In: Physiological reviews. Band 79, Nummer 1 Suppl, Januar 1999, S. S23–S45, PMID 9922375 (Review).
J. M. Pilewski, R. A. Frizzell: Role of CFTR in airway disease. In: Physiological reviews. Band 79, Nummer 1 Suppl, Januar 1999, S. S215–S255, PMID 9922383 (Review).
J. Zabner, J. J. Smith u. a.: Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. In: Molecular cell. Band 2, Nummer 3, September 1998, S. 397–403, PMID 9774978.
J. J. Smith, S. M. Travis u. a.: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. In: Cell. Band 85, Nummer 2, April 1996, S. 229–236, PMID 8612275.
H. Matsui, B. R. Grubb u. a.: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. In: Cell. Band 95, Nummer 7, Dezember 1998, S. 1005–1015, PMID 9875854.
R. Tarran, B. R. Grubb u. a.: The CF salt controversy: in vivo observations and therapeutic approaches. In: Molecular cell. Band 8, Nummer 1, Juli 2001, S. 149–158, PMID 11511368.
W. B. Guggino: Cystic fibrosis and the salt controversy. In: Cell. Band 96, Nummer 5, März 1999, S. 607–610, PMID 10089875 (Review).
W. B. Guggino: Cystic fibrosis salt/fluid controversy: in the thick of it. In: Nature medicine. Band 7, Nummer 8, August 2001, S. 888–889, doi:10.1038/90914, PMID 11479614.
M. E. Krouse: Is cystic fibrosis lung disease caused by abnormal ion composition or abnormal volume? In: The Journal of general physiology. Band 118, Nummer 2, August 2001, S. 219–222, PMID 11479348, PMC 2233826 (freier Volltext) (Review).
K. Ho: The ROMK-cystic fibrosis transmembrane conductance regulator connection: new insights into the relationship between ROMK and cystic fibrosis transmembrane conductance regulator channels. In: Current opinion in nephrology and hypertension. Band 7, Nummer 1, Januar 1998, S. 49–58, PMID 9442363 (Review).
E. F. McKone, S. S. Emerson u. a.: Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. In: The Lancet. Band 361, Nummer 9370, Mai 2003, S. 1671–1676, doi:10.1016/S0140-6736(03)13368-5, PMID 12767731.
E. W. Alton: A mild variant of cystic fibrosis. In: Thorax. Band 51 Suppl 2, August 1996, S. S51–S54, PMID 8869353, PMC 1090707 (freier Volltext) (Review).
M. P. Boyle, K. De Boeck: A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. In: The Lancet. Respiratory medicine. Band 1, Nummer 2, April 2013, S. 158–163, doi:10.1016/S2213-2600(12)70057-7, PMID 24429096 (Review).
E. Kerem: Pharmacologic therapy for stop mutations: how much CFTR activity is enough? In: Current opinion in pulmonary medicine. Band 10, Nummer 6, November 2004, S. 547–552, PMID 15510065 (Review).
M. Haardt, M. Benharouga u. a.: C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. In: The Journal of biological chemistry. Band 274, Nummer 31, Juli 1999, S. 21873–21877, PMID 10419506.
A. M. Cantin, G. Bilodeau u. a.: Oxidant stress suppresses CFTR expression. In: American journal of physiology. Cell physiology. Band 290, Nummer 1, Januar 2006, S. C262–C270, doi:10.1152/ajpcell.00070.2005, PMID 16162662.
A. M. Cantin, J. W. Hanrahan u. a.: Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. In: American journal of respiratory and critical care medicine. Band 173, Nummer 10, Mai 2006, S. 1139–1144, doi:10.1164/rccm.200508-1330OC, PMID 16497995.
E. F. McKone, J. Shao u. a.: Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. In: American journal of respiratory and critical care medicine. Band 174, Nummer 4, August 2006, S. 415–419, doi:10.1164/rccm.200508-1281OC, PMID 16690975, PMC 2648118 (freier Volltext).
T. Flass, M. R. Narkewicz: Cirrhosis and other liver disease in cystic fibrosis. In: Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society. Band 12, Nummer 2, März 2013, S. 116–124, doi:10.1016/j.jcf.2012.11.010, PMID 23266093, PMC 3883947 (freier Volltext).
M. Angelico, C. Gandin u. a.: Gallstones in cystic fibrosis: a critical reappraisal. In: Hepatology (Baltimore, Md.). Band 14, Nummer 5, November 1991, S. 768–775, PMID 1937382.
N. C. Dean, D. H. Van Boerum, T. G. Liou: Rib plating of acute and sub-acute non-union rib fractures in an adult with cystic fibrosis: a case report. In: BMC research notes. Band 7, 2014, S. 681, doi:10.1186/1756-0500-7-681, PMID 25270323, PMC 4197343 (freier Volltext).
R. M. Javier, J. Jacquot: Bone disease in cystic fibrosis: what’s new? In: Joint, bone, spine. Band 78, Nummer 5, Oktober 2011, S. 445–450, doi:10.1016/j.jbspin.2010.11.015, PMID 21233000 (Review).
L. S. Conwell, A. B. Chang: Bisphosphonates for osteoporosis in people with cystic fibrosis. In: The Cochrane database of systematic reviews. Band 3, 2014, S. CD002010, doi:10.1002/14651858.CD002010.pub4, PMID 24627308 (Review).
G. Döring, S. P. Conway: Osteoporosis in cystic fibrosis. In: Jornal de pediatria. Band 84, Nummer 1, 2008, S. 1–3, doi:10.2223/JPED.1749, PMID 18264617.
C. S. Haworth, P. L. Selby u. a.: Osteoporosis in adults with cystic fibrosis. In: Journal of the Royal Society of Medicine. Band 91 Suppl 34, 1998, S. 14–18, PMID 9709383, PMC 1296368 (freier Volltext) (Review).
R. M. Aris, J. B. Renner u. a.: Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. In: Annals of internal medicine. Band 128, Nummer 3, Februar 1998, S. 186–193, PMID 9454526.
E. F. Shead, C. S. Haworth u. a.: Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. In: Journal of cystic fibrosis. Band 9, Nummer 2, März 2010, S. 93–98, doi:10.1016/j.jcf.2009.11.007, PMID 20006563.
E. F. Shead, C. S. Haworth u. a.: Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. In: American journal of respiratory and critical care medicine. Band 174, Nummer 3, August 2006, S. 306–311, doi:10.1164/rccm.200512-1943OC, PMID 16675777.
E. F. Shead, C. S. Haworth u. a.: Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. In: Thorax. Band 62, Nummer 7, Juli 2007, S. 650–651, doi:10.1136/thx.2006.075887, PMID 17600296, PMC 2117234 (freier Volltext).
L. Le Heron, C. Guillaume u. a.: Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. In: Journal of cystic fibrosis. Band 9, Nummer 1, Januar 2010, S. 69–72, doi:10.1016/j.jcf.2009.11.005, PMID 20005786.
E. Shane, S. J. Silverberg u. a.: Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. In: The American journal of medicine. Band 101, Nummer 3, September 1996, S. 262–269, doi:10.1016/S0002-9343(96)00155-6, PMID 8873487.
R. Z. Sokol: Infertility in men with cystic fibrosis. In: Current opinion in pulmonary medicine. Band 7, Nummer 6, November 2001, S. 421–426, PMID 11706320 (Review).
W. Lissens, I. Liebaers: The genetics of male infertility in relation to cystic fibrosis. In: Baillière’s clinical obstetrics and gynaecology. Band 11, Nummer 4, Dezember 1997, S. 797–817, PMID 9692018 (Review).
J. Yu, Z. Chen u. a.: CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. In: Human reproduction. Band 27, Nummer 1, Januar 2012, S. 25–35, doi:10.1093/humrep/der377, PMID 22081250 (Review).
J. Massie, B. Clements: Diagnosis of cystic fibrosis after newborn screening: the Australasian experience–twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group. In: Pediatric pulmonology. Band 39, Nummer 5, Mai 2005, S. 440–446, doi:10.1002/ppul.20191, PMID 15704202 (Review).
D. S. Hardin: Growth problems and growth hormone treatment in children with cystic fibrosis. In: Journal of pediatric endocrinology & metabolism. Band 15 Suppl 2, Mai 2002, S. 731–735, PMID 12092687 (Review).
D. S. Hardin, C. Ahn u. a.: Growth hormone improves bone mineral content in children with cystic fibrosis. In: Journal of pediatric endocrinology & metabolism. Band 18, Nummer 6, Juni 2005, S. 589–595, PMID 16042327.
V. Teichgräber, M. Ulrich u. a.: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. In: Nature medicine. Band 14, Nummer 4, April 2008, S. 382–391, doi:10.1038/nm1748, PMID 18376404.
J. Kornhuber, M. Muehlbacher u. a.: Identification of novel functional inhibitors of acid sphingomyelinase. In: PloS one. Band 6, Nummer 8, 2011, S. e23852, doi:10.1371/journal.pone.0023852, PMID 21909365, PMC 3166082 (freier Volltext).
E. M. Welch, E. R. Barton u. a.: PTC124 targets genetic disorders caused by nonsense mutations. In: Nature. Band 447, Nummer 7140, Mai 2007, S. 87–91, doi:10.1038/nature05756, PMID 17450125.
G. L. McPhail, J. P. Clancy: Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. In: Drugs of today. Band 49, Nummer 4, April 2013, S. 253–260, doi:10.1358/dot.2013.49.4.1940984, PMID 23616952.
K. Kotha, J. P. Clancy: Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. In: Therapeutic advances in respiratory disease. Band 7, Nummer 5, Oktober 2013, S. 288–296, doi:10.1177/1753465813502115, PMID 24004658 (Review).
I. Sermet-Gaudelus: Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. In: European respiratory review. Band 22, Nummer 127, März 2013, S. 66–71, doi:10.1183/09059180.00008512, PMID 23457167 (Review).
J. C. Davies, E. W. Alton: Design of gene therapy trials in CF patients. In: Methods in molecular biology (Clifton, N.J.). Band 741, 2011, S. 55–68, doi:10.1007/978-1-61779-117-8_5, PMID 21594778 (Review).
I. Sermet-Gaudelus, K. D. Boeck u. a.: Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. In: American journal of respiratory and critical care medicine. Band 182, Nummer 10, November 2010, S. 1262–1272, doi:10.1164/rccm.201001-0137OC, PMID 20622033.
T. Iannitti, B. Palmieri: Clinical and experimental applications of sodium phenylbutyrate. In: Drugs in R&D. Band 11, Nummer 3, September 2011, S. 227–249, doi:10.2165/11591280-000000000-00000, PMID 21902286, PMC 3586072 (freier Volltext) (Review).
P. L. Zeitlin, M. Diener-West u. a.: Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. In: Molecular therapy. Band 6, Nummer 1, Juli 2002, S. 119–126, doi:10.1006/mthe.2002.0639, PMID 12095312.
M. Favia, M. T. Mancini u. a.: Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. In: American journal of physiology. Lung cellular and molecular physiology. Band 307, Nummer 1, Juli 2014, S. L48–L61, doi:10.1152/ajplung.00305.2013, PMID 24816489.
J. F. Collawn, L. Fu u. a.: Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator. In: American journal of physiology. Band 307, Nummer 6, September 2014, S. L431–L434, doi:10.1152/ajplung.00177.2014, PMID 25063802, PMC 4166784 (freier Volltext) (Review).
T. S. Cohen, A. Prince: Cystic fibrosis: a mucosal immunodeficiency syndrome. In: Nature medicine. Band 18, Nummer 4, April 2012, S. 509–519, doi:10.1038/nm.2715, PMID 22481418, PMC 3577071 (freier Volltext) (Review).
L. L. Clarke, B. R. Grubb u. a.: Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. In: Science. Band 257, Nummer 5073, August 1992, S. 1125–1128, PMID 1380724.
J. N. Snouwaert, K. K. Brigman u. a.: An animal model for cystic fibrosis made by gene targeting. In: Science. Band 257, Nummer 5073, August 1992, S. 1083–1088, PMID 1380723.
R. Rozmahel, M. Wilschanski u. a.: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. In: Nature genetics. Band 12, Nummer 3, März 1996, S. 280–287, doi:10.1038/ng0396-280, PMID 8589719.
C. S. Rogers, Y. Hao u. a.: Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. In: The Journal of clinical investigation. Band 118, Nummer 4, April 2008, S. 1571–1577, doi:10.1172/JCI34773, PMID 18324337, PMC 2265103 (freier Volltext).
Y. Song, W. Namkung u. a.: Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: dependence on Na+ and Cl- channel function. In: American journal of physiology. Lung cellular and molecular physiology. Band 297, Nummer 6, Dezember 2009, S. L1131–L1140, doi:10.1152/ajplung.00085.2009, PMID 19820035, PMC 2793186 (freier Volltext).
X. Sun, H. Sui u. a.: Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. In: The Journal of clinical investigation. Band 120, Nummer 9, September 2010, S. 3149–3160, doi:10.1172/JCI43052, PMID 20739752, PMC 2929732 (freier Volltext).
N. W. Keiser, J. F. Engelhardt: New animal models of cystic fibrosis: what are they teaching us? In: Current opinion in pulmonary medicine. Band 17, Nummer 6, November 2011, S. 478–483, doi:10.1097/MCP.0b013e32834b14c9, PMID 21857224, PMC 3596000 (freier Volltext) (Review).
P. B. Davis: Cystic fibrosis since 1938. In: American journal of respiratory and critical care medicine. Band 173, Nummer 5, März 2006, S. 475–482, doi:10.1164/rccm.200505-840OE, PMID 16126935 (Review).
L. K. Tuchman, L. A. Schwartz u. a.: Cystic fibrosis and transition to adult medical care. In: Pediatrics. Band 125, Nummer 3, März 2010, S. 566–573, doi:10.1542/peds.2009-2791, PMID 20176665 (Review).
J. L. Kreindler, V. A. Miller: Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care. In: Patient preference and adherence. Band 7, 2013, S. 1221–1226, doi:10.2147/PPA.S37710, PMID 24376344, PMC 3864992 (freier Volltext) (Review).
B. S. Quon, W. D. Bentham u. a.: Prevalence of Symptoms of Depression and Anxiety in Adults With Cystic Fibrosis Based on the PHQ-9 and GAD-7 Screening Questionnaires. In: Psychosomatics. [elektronische Veröffentlichung vor dem Druck] Juni 2014, doi:10.1016/j.psym.2014.05.017, PMID 25556569.
J. O. Warner, A. P. Norman, J. F. Soothill: Cystic fibrosis heterozygosity in the pathogenesis of allergy. In: The Lancet. Band 1, Nummer 7967, Mai 1976, S. 990–991, PMID 57442.
M. Dahl, A. Tybjaerg-Hansen u. a.: DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. In: The Lancet. Band 351, Nummer 9120, Juni 1998, S. 1911–1913, PMID 9654257.
S. A. Schroeder, D. M. Gaughan, M. Swift: Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. In: Nature medicine. Band 1, Nummer 7, Juli 1995, S. 703–705, PMID 7585155.
N. Maurya, S. Awasthi, P. Dixit: Association of CFTR gene mutation with bronchial asthma. In: The Indian journal of medical research. Band 135, Nummer 4, April 2012, S. 469–478, PMID 22664493, PMC 3385229 (freier Volltext) (Review).
T. A. VanWort, J. A. Lee u. a.: Female cystic fibrosis mutation carriers and assisted reproductive technology: does carrier status affect reproductive outcomes? In: Fertility and sterility. Band 102, Nummer 5, November 2014, S. 1324–1330, doi:10.1016/j.fertnstert.2014.07.1234, PMID 25217870.
I. Gallego Romero, C. Ober: CFTR mutations and reproductive outcomes in a population isolate. In: Human genetics. Band 122, Nummer 6, Januar 2008, S. 583–588, doi:10.1007/s00439-007-0432-1, PMID 17901983.
M. Dahl, A. Tybjaerg-Hansen u. a.: Cystic fibrosis Delta F508 heterozygotes, smoking, and reproduction: studies of 9141 individuals from a general population sample. In: Genomics. Band 50, Nummer 1, Mai 1998, S. 89–96, doi:10.1006/geno.1998.5272, PMID 9628826.
S. V. Raju, J. H. Tate u. a.: Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. In: Respiratory research. Band 15, 2014, S. 18, doi:10.1186/1465-9921-15-18, PMID 24517344, PMC 3925354 (freier Volltext).
C. R. Lake, P. B. Davis u. a.: Electrolytes and norepinephrine levels in blood of patients with cystic fibrosis. In: Clinica Chimica Acta. Band 92, Nummer 2, März 1979, S. 141–146, PMID 487568.
J. Lieberman, S. Rodbard: Low blood pressure in young adults with cystic fibrosis: an effect of chronic salt loss in sweat? In: Annals of internal medicine. Band 82, Nummer 6, Juni 1975, S. 806–808, PMID 1138590.
J. J. Guo, D. A. Stoltz u. a.: Genotype-specific alterations in vascular smooth muscle cell function in cystic fibrosis piglets. In: Journal of cystic fibrosis. Band 13, Nummer 3, Mai 2014, S. 251–259, doi:10.1016/j.jcf.2013.10.009, PMID 24183914, PMC 3972271 (freier Volltext).
V. A. Peotta, P. Bhandary u. a.: Reduced blood pressure of CFTR-F508del carriers correlates with diminished arterial reactivity rather than circulating blood volume in mice. In: PloS one. Band 9, Nummer 5, 2014, S. e96756, doi:10.1371/journal.pone.0096756, PMID 24801204, PMC 4011854 (freier Volltext).
N. Morral, V. Nunes u. a.: Microsatellite haplotypes for cystic fibrosis: mutation frameworks and evolutionary tracers. In: Human molecular genetics. Band 2, Nummer 7, Juli 1993, S. 1015–1022, PMID 7689896.
S. Rendine, F. Calafell u. a.: Genetic history of cystic fibrosis mutations in Italy. I. Regional distribution. In: Annals of Human Genetics. Band 61, 1997, S. 411–424, doi:10.1046/j.1469-1809.1997.6150411.x, PMID 9459003.
C. Wiuf: Do delta F508 heterozygotes have a selective advantage? In: Genetical research. Band 78, Nummer 1, August 2001, S. 41–47, PMID 11556136.
M. Claustres: Molecular pathology of the CFTR locus in male infertility. In: Reproductive biomedicine online. Band 10, Nummer 1, Januar 2005, S. 14–41, PMID 15705292 (Review).
S. E. Gabriel, K. N. Brigman u. a.: Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. In: Science. Band 266, Nummer 5182, Oktober 1994, S. 107–109, PMID 7524148.
G. B. Pier, M. Grout u. a.: Salmonella typhi uses CFTR to enter intestinal epithelial cells. In: Nature. Band 393, Nummer 6680, Mai 1998, S. 79–82, doi:10.1038/30006, PMID 9590693.
J. B. Lyczak, G. B. Pier: Salmonella enterica serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. In: Infection and immunity. Band 70, Nummer 11, November 2002, S. 6416–6423, PMID 12379722, PMC 130400 (freier Volltext).
E. van de Vosse, S. Ali u. a.: Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR). In: Human genetics. Band 118, Nummer 1, Oktober 2005, S. 138–140, doi:10.1007/s00439-005-0005-0, PMID 16078047.
E. M. Poolman, A. P. Galvani: Evaluating candidate agents of selective pressure for cystic fibrosis. In: Journal of the Royal Society. Band 4, Nummer 12, Februar 2007, S. 91–98, doi:10.1098/rsif.2006.0154, PMID 17015291, PMC 2358959 (freier Volltext).
C. M. Anderson, J. Allan, P. G. Johansen: Comments on the possible existence and nature of a heterozygote advantage in cystic fibrosis. In: Bibliotheca paediatrica. Band 86, 1967, S. 381–387, PMID 6054652.
J. K. Tobacman: Does deficiency of arylsulfatase B have a role in cystic fibrosis? In: Chest. Band 123, Nummer 6, Juni 2003, S. 2130–2139, PMID 12796199 (Review).
A. L. Hughes, R. Friedman, M. Murray: Genomewide pattern of synonymous nucleotide substitution in two complete genomes of Mycobacterium tuberculosis. In: Emerging infectious diseases. Band 8, Nummer 11, November 2002, S. 1342–1346, doi:10.3201/eid0811.020064, PMID 12453367, PMC 2738538 (freier Volltext).
D. Saleheen, P. M. Frossard: The cradle of the deltaF508 mutation. In: Journal of Ayub Medical College, Abbottabad. Band 20, Nummer 4, 2008, S. 157–160, PMID 19999232 (Review).
R. Busch: On the history of cystic fibrosis. In: Acta Universitatis Carolinae. Medica. Band 36, Nummer 1–4, 1990, S. 13–15, PMID 2130674 (Review).
C. Falkman: Cystic fibrosis–a psychological study of 52 children and their families. In: Acta paediatrica Scandinavica. Supplement. Nummer 269, 1977, S. 1–93, PMID 274900.
C. U. Lowe, C. D. May, S. C. Reed: Fibrosis of the pancreas in infants and children; a statistical study of clinical and hereditary features. In: American journal of diseases of children. Band 78, Nummer 3, September 1949, S. 349–374, doi:10.1001/archpedi.1949.02030050362008, PMID 18138931.
R. C. Darling, P. A. di Sant’Agnese u. a.: Electrolyte abnormalities of the sweat in fibrocystic disease of the pancreas. In: The American journal of the medical sciences. Band 225, Nummer 1, Januar 1953, S. 67–70, PMID 13007698.
L. E. Gibson, R. E. Cooke: A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. In: Pediatrics. Band 23, Nummer 3, März 1959, S. 545–549, PMID 13633369.
P. M. Quinton: Chloride impermeability in cystic fibrosis. In: Nature. Band 301, Nummer 5899, Februar 1983, S. 421–422, PMID 6823316.
R. G. Knowlton, O. Cohen-Haguenauer u. a.: A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. In: Nature. Band 318, Nummer 6044, 1985, S. 380–382, PMID 2999611.
J. M. Rommens, M. C. Iannuzzi u. a.: Identification of the cystic fibrosis gene: chromosome walking and jumping. In: Science. Band 245, Nummer 4922, September 1989, S. 1059–1065, PMID 2772657.